Ovarian Reserve Screening Across Reproductive Life Stages

Abstract

Ovarian reserve screening has become a cornerstone in reproductive medicine, enabling clinicians to assess the quantity and, to some extent, the quality of the ovarian follicular pool across a woman's lifespan. This review systematically evaluates the current evidence and clinical practices pertaining to ovarian reserve testing, spanning from adolescence through perimenopause. It explores the epidemiology, pathophysiology, risk factors, clinical features, and diagnostic modalities, and also critically examines emerging biomarkers, recent advances, and evidence-based guideline recommendations. The review highlights the implications for fertility preservation, counseling, and the management of reproductive-age women, providing a comprehensive synthesis for healthcare professionals involved in women's health and reproductive endocrinology.

Introduction

The assessment of ovarian reserve is integral to reproductive endocrinology and infertility practice, guiding clinical decision-making for women seeking conception, fertility preservation, or management of gynecologic conditions. Ovarian reserve refers to the functional potential of the ovary, primarily determined by the number and quality of remaining primordial follicles. With the increasing trend of delayed childbearing and advances in assisted reproductive technologies, the demand for reliable ovarian reserve screening across various reproductive life stages has grown substantially. This review aims to provide an evidence-based overview of ovarian reserve assessment, highlighting clinical relevance, advances in biomarker development, and practical implications for patient care.

Epidemiology / Disease Burden

The decline in ovarian reserve is a physiological process that accelerates with advancing age, but the rate and pattern exhibit significant inter-individual variability. Epidemiological studies indicate that approximately 10% of women experience diminished ovarian reserve (DOR) before the age of 40, with prevalence increasing to over 50% by the late 30s. The burden of DOR is compounded by social trends of delayed childbearing, increased use of gonadotoxic therapies, and environmental exposures. Globally, infertility affects 8-12% of reproductive-aged couples, with ovarian reserve depletion accounting for a substantial proportion of female-factor infertility. Early identification of reduced reserve is clinically valuable for counseling and timely intervention.

Pathophysiology

Ovarian reserve is established during fetal life when the primordial follicle pool reaches its peak, followed by a continuous, non-renewable decline due to atresia and ovulation. The depletion of follicles is governed by genetic, hormonal, and environmental factors. Mechanistically, the loss of oocyte quality with age is attributed to mitochondrial dysfunction, increased oxidative stress, and accumulating DNA damage. Pathological conditions such as autoimmune disorders, endometriosis, and iatrogenic insults (e.g., chemotherapy, pelvic radiation) can accelerate follicular depletion. Variations in genes involved in folliculogenesis, such as FMR1, BMP15, and GDF9, have also been implicated in premature ovarian insufficiency (POI).

Risk Factors

Risk factors for reduced ovarian reserve are multifactorial and include advanced maternal age, family history of POI, genetic syndromes (e.g., Turner syndrome, Fragile X premutation), prior ovarian surgery, pelvic irradiation or chemotherapy, severe endometriosis, autoimmune diseases, and lifestyle factors such as smoking. Environmental toxins, obesity, and chronic stress have emerging evidence of association with accelerated follicular loss. Recognizing these risk factors is pivotal for targeted screening and preventive strategies, especially in high-risk populations.

Clinical Features

Clinically, diminished ovarian reserve may be asymptomatic until a woman presents with infertility or menstrual irregularities. Subtle changes include shortened menstrual cycles, reduced menstrual flow, and, in advanced cases, symptoms of hypoestrogenism. Women with POI may experience vasomotor symptoms, mood disturbances, and increased cardiovascular and bone health risks. The absence of overt symptoms underscores the importance of proactive screening in at-risk individuals.

Diagnosis

Diagnosis of ovarian reserve status relies on a combination of clinical assessment, menstrual history, and biochemical and ultrasonographic markers. The mainstays of laboratory evaluation include serum anti-Müllerian hormone (AMH), baseline follicle-stimulating hormone (FSH), and estradiol levels, ideally measured in the early follicular phase. AMH is the most robust and cycle-independent marker, reflecting the quantity of small antral follicles. Antral follicle count (AFC) via transvaginal ultrasound provides direct visualization of the follicular pool. Other dynamic tests, such as clomiphene citrate challenge and exogenous FSH ovarian reserve tests, have largely been supplanted by AMH and AFC. Interpretation of these markers must account for inter-assay variability, ethnic differences, and clinical context.

Treatment & Management

The management of women with reduced ovarian reserve is individualized, focusing on fertility counseling, optimization of modifiable risk factors, and timely referral for assisted reproductive technologies (ART) when indicated. For women desiring fertility preservation, options include oocyte or embryo cryopreservation, particularly prior to gonadotoxic therapy or anticipated ovarian surgery. In ART cycles, protocols may be adjusted to maximize oocyte yield, with consideration of adjuvant therapies such as growth hormone or androgens, though robust evidence is limited. Hormone replacement therapy is recommended for women with POI to mitigate long-term health risks of estrogen deficiency. Multidisciplinary care involving reproductive endocrinologists, oncologists, and genetic counselors is often warranted.

Recent Advances / Emerging Therapies

Recent advances in ovarian reserve assessment include the refinement of automated AMH assays, which have improved reproducibility and predictive value. Emerging biomarkers such as inhibin B, ovarian stromal blood flow, and genetic profiling are under investigation for enhanced prognostication. Innovations in ovarian tissue cryopreservation and transplantation offer fertility restoration for select patients. Experimental therapies targeting mitochondrial function and follicular activation pathways hold promise but require further validation in clinical trials. Digital health tools and machine learning models are also being explored for individualized ovarian aging prediction.

Guideline Recommendations

Professional societies such as the American Society for Reproductive Medicine (ASRM), the European Society of Human Reproduction and Embryology (ESHRE), and the National Institute for Health and Care Excellence (NICE) recommend ovarian reserve testing for women at risk of DOR, those considering ART, or prior to gonadotoxic exposure. Routine screening in the general population is not currently endorsed due to limited predictive value for natural fertility. Guidelines emphasize the importance of comprehensive counseling regarding test interpretation, limitations, and implications for reproductive planning. Regular updates to guidelines reflect evolving evidence and technological advancements.

Conclusion

Ovarian reserve screening is a cornerstone of reproductive medicine, providing critical information for fertility counseling, risk stratification, and clinical management across the reproductive lifespan. The integration of robust biomarkers, individualized risk assessment, and evidence-based interventions has improved outcomes for women with diminished ovarian reserve. Ongoing research into novel diagnostic tools and therapeutic strategies holds potential to further enhance reproductive care. Clinicians must remain updated on guideline recommendations and emerging evidence to optimize patient-centered decision-making in this dynamic field.